Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Human-Recombinant-Insulin"

1 News Found

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI
Drug Approval | November 29, 2025

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States

Latest Stories

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

Mangalam Drugs receives Rs. 15 crore repeat export order

Cipla opens India's First dedicated lung health diagnostics center in Delhi

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Future of manufacturing lies in mobility based manufacturing: Sandeep Rathi, Founder & CEO, Sierra Instrumentation & Controls
Future of manufacturing lies in mobility based manufacturing: Sandeep Rathi, Founder & CEO, Sierra Instrumentation & Controls
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Packaging